DS-Connect®: The Down Syndrome Registry
Part of paid clinical trials in Aurora, Colorado.
- Sponsor
- University of Colorado, Denver
- Study ID
- NCT01950624
- Status
- Recruiting
Conditions
- Down Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
The goal of this study is to develop a registry for Down syndrome (DS) to facilitate research participation by individuals with Down syndrome. DS-Connect® is an online survey tool designed to collect demographic data and health information from individuals with DS. It is open to all people with Down syndrome. The purposes of DS-Connect® are: 1. To identify the various phenotypic manifestations of DS. 2. To identify individuals with DS who may be eligible for research studies or new clinical trials, based on specific information about their diagnosis and health history.
Key Dates
- Start date
- Sep 6, 2013
- Status verified
- Jan 2025
- Primary completion
- Jun 30, 2035
- Completion
- Jun 30, 2035
Study Design
- Enrollment
- 100,000 participants (estimated)
Arms
- Arm: Down syndrome cohortIndividuals who have a diagnosis of complete trisomy 21, translocation Down syndrome or mosaic Down syndrome.
Primary Outcome Measure
To determine the prevalence of the various co-occurring conditions in Down syndrome. [ Time Frame: Through study completion, up to 10 years ]
Central Contacts
- Anne Fiala(303) 724-6599
- Angela Rachubinski, PhD
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Linda Crnic Institute for Down Syndrome | Aurora | Colorado | 80045 |
Find similar trials in Aurora, CO
Related Studies
- The Human Trisome ProjectRecruiting · University of Colorado, Denver · Denver, Colorado
- Trial-Ready Cohort-Down Syndrome (TRC-DS)Recruiting · University of Southern California · Phoenix, Arizona
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Recruiting · Duke University · Phoenix, Arizona
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)PHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama